| Literature DB >> 29558945 |
Maolin Gu1, Jing Qiu2, Daoxia Guo3, Yunfang Xu1, Xingxiang Liu1, Chong Shen4, Chen Dong5.
Abstract
BACKGROUND: Recent GWAS-associated studies reported that single nucleotide polymorphisms (SNPs) in ABCB1, TGFβ1, XRCC1 genes were associated with hepatitis A virus (HAV) infection, and variants of APOA4 and APOE genes were associated with and hepatitis E virus (HEV) infection in US population. However, the associations of these loci with HAV or HEV infection in Chinese Han population remain unclear.Entities:
Keywords: Hepatitis A virus; Hepatitis E virus; Single-nucleotide polymorphism
Mesh:
Substances:
Year: 2018 PMID: 29558945 PMCID: PMC5859746 DOI: 10.1186/s12985-018-0962-2
Source DB: PubMed Journal: Virol J ISSN: 1743-422X Impact factor: 4.099
Characteristic of HAV IgG and HEV IgG antibody in studied population
| Characteristic | HAV IgG | HEV IgG | ||||||
|---|---|---|---|---|---|---|---|---|
| Positive ( | Negative( | χ2/ | Positive ( | Negative( | χ2/ | P-value | ||
| Age (Years) | 45.33 ± 8.35 | 42.66 ± 8.76 | 7.376 | <0.001 | 45.89 ± 8.53 | 44.24 ± 8.47 | 4.884 | <0.001 |
| 30- | 519(65.5%) | 2327(34.5%) | 174(22.0%) | 618(70.8%) | ||||
| 40- | 1284(80.6%) | 310(19.4%) | 473(29.7%) | 1120(70.3%) | ||||
| 50- | 427(83.1%) | 87(16.9%) | 88.838 | <0.001 | 171(33.4%) | 341(66.6%) | 29.649 | <0.001 |
| 60- | 127(79.4%) | 33(20.6%) | 59(36.9%) | 101(63.1%) | ||||
| 70- | 18(81.8%) | 4(18.2%) | 8(36.4%) | 14(63.6%) | ||||
| Gender | ||||||||
| Male | 1299(54.7%) | 356(50.4%) | 4.130 | 0.042 | 486(54.9%) | 1166(53.1%) | 0.795 | 0.373 |
| Female | 1076(45.3%) | (35,149.6%) | 399(45.1%) | 1028(46.9%) | ||||
Analysis on the association between SNPs selected from GWAS and anti-HAV IgG seropositivity
| Gene nomenclature | SNP | Anti-HAV IgG | WT/HT/MT | OR(95%CI)a | ||
|---|---|---|---|---|---|---|
| Additive | Dominant | Recessive | ||||
| CAT | rs769214 | GG/GA/AA | ||||
| Positive | 1190/975/201 | 0.979(0.858–1.117) | 0.966(0.815–1.144) | 1.000(0.738–1.355) | ||
| Negative | 347/298/60 | |||||
| XRCC1 | rs1001581 | AA/AG/GG | ||||
| Positive | 929/1040/403 | 0.920(0.817–1.036) | 0.836(0.700–0.998) | 0.995(0.794–1.247) | ||
| Negative | 247/338/120 | |||||
| ABCB1 | rs1045642 | CC/CT/TT | ||||
| Positive | 913/1107/346 | 0.862(0.763–0.974) | 0.835(0.699–0.997) | 0.802(0.638–1.007) | ||
| Negative | 245/334/123 | |||||
| TGFβ1 | rs1800469 | CC/CT/TT | ||||
| Positive | 600/1194/572 | 0.918(0.813–1.037) | 0.878(0.719–1.073) | 0.908(0.747–1.104) | ||
| Negative | 162/362/181 | |||||
| CYP2E1 | rs2031920 | CC/CT/TT | ||||
| Positive | 1471/780/113 | 0.868(0.754–1.001) | 0.851(0.716–1.012) | 0.799(0.551–1.159) | ||
| Negative | 409/254/41 | |||||
WT wild type, HT heterozygote, MT mutant type
a: Adjusted for age and sex
Gender-stratification analysis on the association between selected SNPs and anti-HAV seropositivity
| Gene nomenclature | SNP | Stratum | Anti-HAV IgG | WT/HT/MT | OR(95%CI)/ | ||
|---|---|---|---|---|---|---|---|
| Additive | Dominant | Recessive | |||||
| CAT | rs769214 | GG/GA/AA | |||||
| Male | positive | 654/525/115 | 0.955(0.797–1.144) | 0.920(0.727–1.163) | 1.019(0.673–1.544) | ||
| negative | 172/152/31 | ||||||
| Female | positive | 536/450/86 | 0.994(0.822–1.201) | 1.000(0.786–1.273) | 0.965(0.622–1.498) | ||
| negative | 175/146/29 | ||||||
| XRCC1 | rs1001581 | AA/AG/GG | |||||
| Male | positive | 491/577/229 | 0.911(0.774–1.073) | 0.824(0.644–1.055) | 0.978(0.720–1.328) | ||
| negative | 119/173/64 | ||||||
| Female | positive | 438/463/174 | 0.925(0.781–1.096) | 0.842(0.656–1.081) | 1.010(0.727–1.404) | ||
| negative | 128/165/56 | ||||||
| ABCB1 | rs1045642 | CC/CT/TT | |||||
| Male | positive | 497/624/174 | 0.848(0.714–1.007) | 0.827(0.646–1.059) | 0.773(0.561–1.067) | ||
| negative | 120/174/59 | ||||||
| Female | positive | 416/483/172 | 0.900(0.759–1.067) | 0.879(0.684–1.129) | 0.852(0.621–1.169) | ||
| negative | 125/160/64 | ||||||
| TGFβ1 | rs1800469 | CC/CT/TT | |||||
| Male | positive | 350/637/307 | 0.910(0.771–1.074) | 0.820(0.623–1.079) | 0.947(0.721–1.244) | ||
| negative | 83/185/88 | ||||||
| Female | positive | 250/557/265 | 0.947(0.796–1.127) | 0.962(0.721–1.283) | 0.904(0.687–1.190) | ||
| negative | 79/177/93 | ||||||
| CYP2E1 | rs2031920 | CC/CT/TT | |||||
| Male | positive | 795/438/61 | 0.865(0.712–1.051) | 0.868(0.684–1.102) | 0.714(0.435–1.171) | ||
| negative | 206/126/23 | ||||||
| Female | positive | 676/342/52 | 0.860(0.702–1.052) | 0.810(0.633–1.037) | 0.938(0.542–1.628) | ||
| negative | 203/128/18 | ||||||
WT wild type, HT heterozygote, MT mutant type
a Adjusted for age
Analysis on the associations between SNPs selected from GWAS and anti-HEV IgG seropositivity
| Gene nomenclature | SNP | Anti-HEV IgG | WT/HT/MT | OR(95%CI)a | ||
|---|---|---|---|---|---|---|
| Additive | Dominant | Recessive | ||||
| APOA4 | rs1268354 | CC/CT/TT | ||||
| Positive | 341/413/129 | 0.929(0.828–1.043) | 0.88(0.748–1.034) | 0.967(0.775–1.208) | ||
| Negative | 778/1083/324 | |||||
| APOE | rs405509 | TT/TG/GG | ||||
| Positive | 443/377/62 | 0.996(0.88–1.127) | 1.035(0.884–1.211) | 0.863(0.639–1.166) | ||
| Negative | 1120/886/182 | |||||
| rs7412 | CC/CT/TT | |||||
| Positive | 757/122/6 | 0.853(0.694–1.049) | 0.831(0.668–1.034) | 1.148(0.433–3.044) | ||
| Negative | 1820/360/13 | P = 0.131 | ||||
| rs769450 | AA/AG/GG | |||||
| Positive | 556/300/29 | 1.044(0.909–1.2) | 1.091(0.927–1.284) | 0.831(0.542–1.274) | ||
| Negative | 1426/677/90 | P = 0.542 | ||||
WT wild type, HT heterozygote, MT mutant type
a: Adjusted for age and sex
Gender-stratification analysis on the association between selected SNPs and anti-HEV IgG seropositivity
| Gene nomenclature | SNP | Stratum | Anti-HEV IgG | WT/HT/MT | OR(95%CI)/ | ||
|---|---|---|---|---|---|---|---|
| Additive | Dominant | Recessive | |||||
| APOA4 | rs1268354 | CC/CT/TT | |||||
| Male | positive | 187/223/75 | 0.963(0.823–1.126) | 0.893(0.754–1.059) | 0.883(0.708–1.101) | ||
| negative | 412/587/163 | ||||||
| Female | positive | 154/190/54 | 0.88(0.692–1.117) | 1.095(0.812–1.476) | 0.833(0.597–1.162) | ||
| negative | 366/496/161 | ||||||
| APOE | rs405509 | TT/TG/GG | |||||
| Male | positive | 243/209/32 | 0.941(0.796–1.112) | 1.076(0.894–1.294) | 0.998(0.806–1.235) | ||
| negative | 581/472/111 | ||||||
| Female | positive | 200/168/30 | 1.089(0.864–1.374) | 0.713(0.472–1.075) | 1.114(0.714–1.737) | ||
| negative | 539/414/71 | ||||||
| rs7412 | CC/CT/TT | ||||||
| Male | positive | 422/63/1 | 0.707(0.527–0.95) | 1.036(0.775–1.385) | 0.708(0.522–0.96) | ||
| negative | 958/210/6 | ||||||
| Female | positive | 335/59/5 | 0.998(0.728–1.367) | 0.351(0.042–2.958) | 1.895(0.597–6.014) | ||
| negative | 862/159/7 | ||||||
| rs769450 | AA/AG/GG | ||||||
| Male | positive | 297/176/13 | 1.086(0.9–1.311) | 1.004(0.817–1.235) | 1.195(0.959–1.49) | ||
| negative | 758/355/52 | ||||||
| Female | positive | 259/124/16 | 0.988(0.775–1.26) | 0.632(0.34–1.177) | 1.116(0.614–2.027) | ||
| negative | 668/322/38 | ||||||
WT wild type, HT heterozygote, MT mutant type
a Adjusted for age